ZVSA 2.24 ZyVersa Therapeutics, Inc.
| Range: | 1.9-45.5 | Vol Avg: | 103206 | Last Div: | 0 | Changes: | 0.04 |
| Beta: | 0.64 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Feb 11 2022 | Empoloyees: | 7 | ||
| CUSIP: | CIK: | 0001859007 | ISIN: | US98987D2018 | Country: | US | |
| CEO: | Mr. Stephen C. Glover | Website: | https://www.zyversa.com | ||||
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow